Published in Antivir Ther on January 31, 2014
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis (2010) 3.47
Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS (2010) 2.03
Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test. J Clin Microbiol (2006) 1.96
A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. J Infect Dis (2007) 1.56
Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience. CMAJ (2004) 1.50
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis (2011) 1.49
Systematic review of strategies to measure HIV-related diarrhea. HIV Clin Trials (2007) 1.45
A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med (2002) 1.39
Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women. J Infect Dis (2013) 1.25
Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther (2008) 1.21
Confirmatory real-time PCR assay for human papillomavirus (HPV) type 52 infection in anogenital specimens screened for HPV infection with the linear array HPV genotyping test. J Clin Microbiol (2007) 1.20
Medicinal and recreational marijuana use by patients infected with HIV. AIDS Patient Care STDS (2004) 1.20
A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antivir Ther (2005) 1.18
Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study. Int J Epidemiol (2009) 1.17
Use of complementary and alternative medicine by HIV-infected outpatients in Ontario, Canada. AIDS Patient Care STDS (2003) 1.14
Better mind the gap: addressing the shortage of HIV-positive women in clinical trials. AIDS (2010) 1.14
Self-sampling is associated with increased detection of human papillomavirus DNA in the genital tract of HIV-seropositive women. Clin Infect Dis (2005) 1.13
Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One (2011) 1.09
Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. Eur J Clin Pharmacol (2007) 1.09
The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. Qual Life Res (2005) 1.04
SARS outbreak in the Greater Toronto Area: the emergency department experience. CMAJ (2004) 1.04
Representativeness of an HIV cohort of the sites from which it is recruiting: results from the Ontario HIV Treatment Network (OHTN) cohort study. BMC Med Res Methodol (2013) 1.01
Reproducibility of DXA estimations of body fat in HIV lipodystrophy: implications for clinical research. J Clin Densitom (2005) 1.00
A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy. Clin Infect Dis (2013) 0.99
A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Br J Clin Pharmacol (2006) 0.99
The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J Antimicrob Chemother (2006) 0.99
Mortality in HIV-hepatitis C co-infected patients in Canada compared to the general Canadian population (2003-2013). AIDS (2014) 0.98
Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial. J Infect Dis (2010) 0.98
Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. Ann Pharmacother (2013) 0.98
Once daily dosing improves adherence to antiretroviral therapy. AIDS Behav (2011) 0.97
Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada. HIV Clin Trials (2011) 0.96
The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother (2008) 0.95
Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries. BMC Infect Dis (2010) 0.91
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. AIDS (2015) 0.91
Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy. HIV Clin Trials (2005) 0.90
Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients. HIV Clin Trials (2008) 0.89
CD36 deficiency induced by antiretroviral therapy. AIDS (2002) 0.89
Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapy. HIV Clin Trials (2011) 0.88
Longitudinal trends in antiretroviral use in a cohort of men and women in Ontario, Canada. AIDS Patient Care STDS (2006) 0.87
A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102). HIV Clin Trials (2004) 0.87
A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis. J Acquir Immune Defic Syndr (2002) 0.86
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings. AIDS (2014) 0.86
Marijuana smoking does not accelerate progression of liver disease in HIV-hepatitis C coinfection: a longitudinal cohort analysis. Clin Infect Dis (2013) 0.86
Evaluation of Stool frequency and stool form as measures of HIV-related diarrhea. HIV Clin Trials (2007) 0.86
Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy? Radiother Oncol (2010) 0.85
Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy. Antivir Ther (2008) 0.85
Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy. J Acquir Immune Defic Syndr (2011) 0.85
A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials (2010) 0.85
Polypharmacy in HIV: impact of data source and gender on reported drug utilization. AIDS Patient Care STDS (2004) 0.85
Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease. Dis Colon Rectum (2014) 0.84
Reassessment of enfuvirtide's role in the management of HIV-1 infection. Expert Opin Pharmacother (2008) 0.84
Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy. HIV Clin Trials (2003) 0.84
Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen. Antivir Ther (2007) 0.83
Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy. Int J Radiat Oncol Biol Phys (2009) 0.83
Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients. MedGenMed (2006) 0.83
Who needs direct-acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV-coinfected individuals. Antivir Ther (2012) 0.83
High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults. HIV Clin Trials (2012) 0.83
Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library. Eur J Immunol (2012) 0.81
Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients. AIDS (2012) 0.81
Critical Review: Review of the Efficacy, Safety, and Pharmacokinetics of Raltegravir in Pregnancy. J Acquir Immune Defic Syndr (2016) 0.80
German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008. Eur J Med Res (2009) 0.78
Canadian consensus guidelines for the management of cytomegalovirus disease in HIV/AIDS. Can J Infect Dis Med Microbiol (2004) 0.78
Safety of pharmacoenhancers for HIV therapy. Expert Rev Clin Pharmacol (2012) 0.78
Mild to moderate symptoms do not correlate with lactate levels in HIV-positive patients on nucleoside reverse transcriptase inhibitors. HIV Clin Trials (2006) 0.78
Design and methods of the MAINTAIN study: a randomized controlled clinical trial of micronutrient and antioxidant supplementation in untreated HIV infection. Contemp Clin Trials (2010) 0.78
Canadian consensus guidelines for the optimal use of maraviroc in the treatment of HIV-infected adults. Can J Infect Dis Med Microbiol (2010) 0.78
CMV retinopathy in the antiretroviral therapy era: prevention, diagnosis, and management. Curr Infect Dis Rep (2012) 0.78
High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine. J Clin Immunol (2014) 0.78
An estimate of the proportion of symptoms reported in self-administered questionnaires that are captured as adverse drug events in an observational database. HIV Clin Trials (2007) 0.77
Effectiveness of step-wise intervention plan for managing nelfinavir-associated diarrhea: a pilot study. HIV Clin Trials (2005) 0.77
Infectious complications of Bio-Alcamid filler used for HIV-related facial lipoatrophy. Clin Infect Dis (2012) 0.77
Recent immigrants show improved clinical outcomes at a tertiary care HIV clinic. Can J Infect Dis Med Microbiol (2012) 0.77
Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections. Expert Rev Anti Infect Ther (2007) 0.77
Frequent injection cocaine use increases the risk of renal impairment among hepatitis C and HIV coinfected patients. AIDS (2016) 0.76
Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study. HIV Clin Trials (2015) 0.76
Canadian Consensus Recommendations for the Optimal Use of Enfuvirtide in HIV/AIDS Patients. Can J Infect Dis Med Microbiol (2006) 0.75
ACP Journal Club: review: Xpert MTB/RIF assay detects extrapulmonary TB in lymph nodes and CSF, but not pleural fluid. Ann Intern Med (2015) 0.75
Etravirine for HIV-I: addressing the limitations of the nonnucleoside reverse transcriptase inhibitor class. J Int Assoc Physicians AIDS Care (Chic) (2009) 0.75
A Multi-State Model Examining Patterns of Transitioning Among States of Engagement in Care in HIV-Positive Individuals Initiating Combination Antiretroviral Therapy. J Acquir Immune Defic Syndr (2016) 0.75
Rosiglitazone for HIV-1 lipoatrophy. Lancet (2004) 0.75
Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairment. Ther Drug Monit (2014) 0.75
Is chromium an important element in HIV-positive patients with metabolic abnormalities? An hypothesis generating pilot study. J Am Coll Nutr (2006) 0.75
Antiretroviral rounds. Too many options? AIDS Clin Care (2009) 0.75
The use of multistate models to examine associations of stress and adherence with transitions among HIV care states observed in a clinical HIV cohort. J Acquir Immune Defic Syndr (2017) 0.75
Value of CT in assessing probable severe acute respiratory syndrome. AJR Am J Roentgenol (2003) 0.75
Which HIV patients should be screened for osteoporosis: an international perspective. Curr Opin HIV AIDS (2016) 0.75
The effect of dairy product ingestion on human immunodeficiency virus-related diarrhea in a sample of predominantly gay men: a randomized, controlled, double-blind, crossover trial. Arch Intern Med (2006) 0.75
Impact of baseline virologic, immunologic, and demographic characteristics on virologic responses in the Gemini study. HIV Clin Trials (2012) 0.75
First-line regimen failure of antiretroviral therapy: a clinical and evidence-based approach. Curr Opin HIV AIDS (2009) 0.75
Factors associated with HIV-positive women carrying pregnancies to term. J Obstet Gynaecol Can (2010) 0.75
Antiretroviral rounds. A patient with multiple resistance mutations and a history of nonadherence. AIDS Clin Care (2006) 0.75
Missed opportunities for hepatocellular carcinoma screening in an HIV/hepatitis C virus-coinfected cohort. Clin Infect Dis (2013) 0.75
Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals. Lancet (2004) 0.75